Potential clinical significance of HBV RNA virus-like particle

Abstract

Abstract: Our recent studies confirmed that the HBV RNAs present in the serum of chronic hepatitisB (CHB) patients are pregenomic RNAs (pgRNAs) with a size of 3.5 kb. These pgRNAs are located in viruslikeparticles whose morphological structure is similar to that of Dan particles. Since pgRNAs can only betranscribed from the covalently closed circular DNA (cccDNA) located in the nuclear of infected hepatocytes,and the production of pgRNAs is not affected by nucleos(t)ide analogues (NUCs), the presence of viral RNAin serum can reflect the presence of cccDNA in hepatocytes and its transcriptional activity in patients treatedwith medication. It can be inferred that serum viral RNA can be used as a potential index for safe withdrawal ofNUCs. Our results based on a small-sample cohort show that the presence of HBV RNA in serum at the time ofdrugs withdrawal is indeed associated with virological rebound after drug withdrawal.

Key words: Hepatitis B, chronic, Hepatitis B virus, Therapy, Nucleot(s)ide analogues

LU Feng-min, WANG Jie, ZHUANG Hui. Potential clinical significance of HBV RNA virus-like particle[J]. Chinese Hepatolgy, 2016, 21(9): 717-718.

References

[1] Kock J, Theilmann L, Galle P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology, 1996, 23: 405-413.
[2] JansenL, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis, 2016, 213: 224-232.
[3] Tsuge M, Murakami E, Imamura M, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol, 2013, 48: 1188-1204.
[4] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61: 66-76.
[5] Wang J, Shen T, Huang X B, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016[Epub ahead of print].
[6] Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet, 2012, 44: 765-769.
[7] Jiang S, Yang Z, Li W, et al. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One, 2012, 7: e40363.
[8] Li X, Zhang J, Yang Z, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol, 2014, 60: 975-984.
[9] Shouval D, Rager-Zisman B, Quan P, et al. Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. J Clin Invest, 1983, 72: 707-717.
[10] Shouval D, Reid LM, Chakraborty PR, et al. Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA. Cancer Res, 1981, 41: 1342-1350.

[1]	WANG Juan-juan, SHI Hong-ying, ZHENG Shi-tan. The clinical characteristics of 11 cases of systemic lupus erythematosus with non primary biliary cirrhosis [J]. Chinese Hepatolgy, 2020, 25(5): 491-493.
[2]	HUANG Shan-shan, ZHAO Jing-ya, CHEN Jie, YANG Yang.. The study on mechanism of prostaglandin E2 promoting replication of hepatitis B virus [J]. Chinese Hepatolgy, 2020, 25(3): 277-281.
[3]	KONG Yuan-yuan, WEI Wei, SHAN Shan, MA Hong, OU Xiao-juan, XU Xiao-yuan, DUAN Zhong-ping, HOU Jin-lin, WEI Lai, YOU Hong, JIA Ji-dong, CR-HepB Group. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis [J]. Chinese Hepatolgy, 2020, 25(2): 123-127.
[4]	WANG Xian, LIN Tao-fa, ZHAN Zhi-yu, WANG Shao-yang. Differential expression of T lymphocyte and NK G2D in patients with chronic HBV infection in different immune states [J]. Chinese Hepatolgy, 2020, 25(2): 131-134.
[5]	HE Ya-jing, ZHANG Zhi-ming, HE Wei-meng, HOU Jin-lin. Efficacy of different anti-viral therapy regimens for HBV related hepatocellular carcinoma receiving radiotherapy [J]. Chinese Hepatolgy, 2019, 24(6): 622-627.
[6]	ZHAO Jing-jing, HAN Fang-zheng. Clinical Study of transient ALT elevation in patients with chronic hepatitis B in the early stage of entecavir treatment [J]. Chinese Hepatolgy, 2019, 24(6): 628-630.
[7]	SU Jin-liang, CHEN Hui, ZHU Li, LU Min-Jia, LI Ming. Expression of toll-like receptor 3 and 4 in peripheral blood mononuclear cells from patients with hepatitis B virus -related acute-on-chronic pre-liver failure [J]. Chinese Hepatolgy, 2019, 24(5): 499-502.
[8]	CAO Xiang-yun, Guan Yan-ping, LI Qian, ZHOU Xiao-min, LIU Gao-wei. Comparison of the effects of tenofovir and telbivudine combined with dual immunization regimen on blocking mother-to-child transmission of HBV during pregnancy [J]. Chinese Hepatolgy, 2019, 24(5): 503-506.
[9]	LI Rong, ZHANG Hang, HUANG Xi-yao, DU Dan. The analysis on association between IL28B single gene polymorphisms and the risk of intrauterine infection of HBV in HBsAg positive pregnant women [J]. Chinese Hepatolgy, 2019, 24(3): 234-238.
[10]	LU Jie, CHEN Li-chang, ZHOU Hui-juan, XIE Qing, LIN Lan-yi. Current status of antiviral therapy for chronic HCV infection in China [J]. Chinese Hepatolgy, 2019, 24(11): 1230-1233.
[11]	GU Jing, CHEN Zu-tao, SUN Wei, GAN Jian-he. Changes of serum alkaline phosphatase in patients with HBV-related acute-on-chronic liver failure and its significance [J]. Chinese Hepatolgy, 2019, 24(11): 1234-1236.
[12]	Li Qing, Lai Rong-tao, Lu Jie, Li Zi-qiang, Xie Qing, Wang Hui, Guo Qing. The role of SUMO specific protease 3 in HBV replication [J]. Chinese Hepatolgy, 2019, 24(1): 31-34.
[13]	XIA Li-fang, GUAN Bo-wen, SHAN Yao-bin, LI Kun-peng, WANG Tong, GUO Tong-sheng. Investigation of occult hepatitis B virus infection [J]. Chinese Hepatolgy, 2018, 23(9): 775-777.
[14]	Du Yu-juan, Wang Jia, Duan Xue-zhang, Sun Jing, He Wei-ping, Zhang Tao. Cyberknife used as downstaging therapy before liver transplantation for patients with hepatocellular carcinoma (report of 2 cases) [J]. Chinese Hepatolgy, 2018, 23(6): 484-487.
[15]	HUANG Shun-mei, WANG Jun-zhong, ZHANG Xiao-yong, LI Bao-lin, SONG Zhi-tao, ZHU Zhen-ni, ZHU Bin, WANG Bao-ju, LU Meng-ji, YANG Dong-liang. Effect of three immunosupressive drugs dexamethasone, cyclophosphamide and tacrolimus on HBV replication in vitro [J]. Chinese Hepatolgy, 2018, 23(5): 391-394.